Skip to content

Total Equity at other companies

Schrodinger logo
SchrodingerSDGR
$313.55M-16.1%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$1.02B+9.7%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$670.81M+39.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$938.08M-8.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.75M-62.5%
ADMA Biologics logo
ADMA BiologicsADMA
$390.33M+4.5%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.57B+341%
Enterprise value$1.57B+425%
P/S855.5×+782×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Absci Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Absci Corporation's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Absci Corporation's total equity?
Absci Corporation (ABSI) reported total equity of $171.97M in Q1 2026.
How has Absci Corporation's total equity changed year-over-year?
Absci Corporation's total equity decreased by 13.5% year-over-year, from $198.8M to $171.97M.
What is the long-term trend for Absci Corporation's total equity?
Over 5 years (2020 to 2025), Absci Corporation's total equity has grown at a 16.2% compound annual growth rate (CAGR), from -$89.43M to $189.45M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.